Australian Life Sciences Stock News

Earlier this week, Citi upgraded Computershare Limited to ‘Buy’ from ‘Neutral’, citing confidence in its growth plans underpinned by recent acquisitions and divestments aimed at improving efficiency and shareholder value. The upgrade highlights how Computershare’s portfolio reshaping and focus on core operations are increasingly influencing how analysts assess its long-term earnings profile. We’ll now explore how Citi’s increased confidence in Computershare’s growth strategy may influence...

Why Liontown is in focus after Bell Potter’s latest commentary Bell Potter’s recent commentary on Liontown (ASX:LTR) has drawn attention to the upcoming production ramp-up at the Kathleen Valley lithium mine and the company’s existing offtake agreements with major electric vehicle and battery customers. See our latest analysis for Liontown. Liontown’s recent news sits against a backdrop of strong momentum, with a 30 day share price return of 41.91%, a 90 day gain of 96.35% and a very large 1...

Xero recently completed the global launch of its new AI-powered analytics capabilities, embedding Syft’s reporting tools directly into its cloud accounting platform for millions of small business customers worldwide. By pairing these analytics features with JAX, its AI financial superagent, Xero is pushing enterprise-grade intelligence directly into everyday small-business workflows. We’ll now explore how embedding AI-driven analytics at scale could influence Xero’s investment narrative and...

IGO (ASX:IGO) is heading into a closely watched update, with investors focusing on its December 2025 quarterly results webcast on 29 January 2026, amid rising interest in battery minerals names. See our latest analysis for IGO. IGO’s share price has moved sharply over the past few months, with a 30 day share price return of 16.38% and a 90 day share price return of 66.92%. The 1 year total shareholder return of 66.92% contrasts with a 3 year total shareholder return of negative 31.69%. This...

Boss Energy (ASX:BOE) is under scrutiny after Goldman Sachs issued a Sell rating, highlighting concerns around the operational efficiency and financial viability of the Honeymoon uranium project and the withdrawal of its Enhanced Feasibility Study. See our latest analysis for Boss Energy. At a share price of A$1.58, Boss Energy has seen a 13.4% decline over the past 90 days, while the 1 year total shareholder return of 44.8% loss contrasts with a 103.6% gain over 5 years. This hints that long...

GQG Partners (ASX:GQG) is back in focus after substantial investor withdrawals over 2025, especially in December. Its defensive stance and limited exposure to leading technology stocks weighed on performance versus benchmarks and stirred growth concerns. See our latest analysis for GQG Partners. Those outflows and the defensive stance have been reflected in the share price. A 7 day share price return of 9.09% and a 30 day share price return of 5.71% have pulled the year to date share price...

Elevra Lithium (ASX:ELV) has outlined a staged expansion plan for its North American Lithium project, targeting earlier capacity increases and lower unit operating costs. This has coincided with the shares reaching a recent 12 month high. See our latest analysis for Elevra Lithium. The recent NAL expansion update and broker attention have coincided with a strong run, with a 30 day share price return of 36.24% and a 90 day share price return of 105.58%. The 1 year total shareholder return of...

Why 4DMedical’s New Capital Raise Matters for Investors 4DMedical (ASX:4DX) has completed a follow on equity offering, raising about A$79.1 million by issuing 20,806,185 ordinary shares at A$3.80 each, which represents a A$0.19 discount per share. See our latest analysis for 4DMedical. 4DMedical’s latest capital raise comes after a sharp shift in sentiment, with a 30 day share price return of 79.51% and a 90 day share price return of 189.46%. Over the longer term, total shareholder return has...

Metals X announced that its Renison joint venture has awarded a front-end engineering and design (FEED) contract to GR Engineering Services for the planned Rentails tin tailings reprocessing plant, with FEED completion targeted for the third quarter of 2026 and a potential final investment decision later that year. This FEED award marks a tangible step toward unlocking additional tin production from historical tailings, which could enhance Renison’s role in global tin supply and extend the...

Emerald Resources NL reported that its 100% owned Okvau Gold Mine in Cambodia produced 25,030 ounces of gold in the December 2025 quarter, with 21,372 ounces poured and 20,410 ounces sold at an average price of US$4,118 per ounce. This update gives investors a clearer view of Okvau’s recent operating throughput and realised pricing, key inputs for assessing project performance and revenue generation. We will now examine how Okvau’s December quarter production and strong realised gold price...

Why quarterly gold production is back in focus for Catalyst Metals Catalyst Metals (ASX:CYL) has drawn fresh attention after reporting an upbeat quarterly gold production update. This coincided with the share price reaching a two month high and has put its operations and current valuation back on investors’ radar. See our latest analysis for Catalyst Metals. The upbeat production update comes after a strong run in the share price, with a 1-day share price return of 14.65%, a 30-day share...

On 15 January 2026, Alcidion Group reported Q2 FY26 results showing a move from net loss to profit, backed by higher revenue, strong cash collections, a solid cash balance and no debt, underpinned by sizeable multi‑year healthcare IT contracts and reaffirmed guidance for positive EBITDA and operating cash flow. A key insight is that recent UK contract wins, including preferred Electronic Patient Record supplier status and Miya Precision expansions, have materially increased contracted...

In recent days, Commonwealth Bank of Australia lifted fixed home loan rates for owner-occupiers and investors by as much as 0.70 percentage points, pushing some three-year rates above 6% and ahead of an anticipated Reserve Bank of Australia cash rate increase in February. This move not only raises borrowing costs for households but also highlights how CBA is positioning its mortgage book in response to persistent inflation and expectations of tighter monetary policy. We’ll now explore how...

In recent days, Canaccord Genuity upgraded Lovisa Holdings from Hold to Buy, pointing to a more attractive risk‑reward profile supported by confidence in fiscal 2027 earnings. The broker highlighted that Lovisa’s expanded store rollout plans and potential operating cost efficiencies could underpin its longer-term earnings potential, despite ongoing concerns around cost growth and modest comparable store sales. We’ll now examine how Canaccord’s upgrade, anchored in Lovisa’s accelerated store...

Recent analyst downgrades of Fortescue (ASX:FMG) after a 55% share price rally have sharpened attention on iron ore price assumptions, valuation, and softer profit and revenue trends ahead of the December quarter report. See our latest analysis for Fortescue. Fortescue’s recent analyst downgrades, option conversions and employee equity grants sit against a backdrop of a strong 1 year total shareholder return of 27.85% and a 12.74% 3 month share price return. This suggests momentum has been...

Champion Iron Limited recently reported that railway services on the Quebec North Shore and Labrador Railway have resumed after a December 28, 2025 derailment, allowing high‑purity iron ore concentrate stockpiled at its Bloom Lake mine to begin moving again toward the port of Sept‑Îles. Although mine operations were not materially disrupted, the incident underscored how dependent Champion Iron’s sales and logistics are on a single rail corridor and the importance of its collaboration with...

Recent news shows Telix Pharmaceuticals continuing to build out its radiopharmaceutical franchise, with Illuccix now commercially available in 17 countries and preparations under way to launch Gozellix, supported by expanded manufacturing and distribution capacity via the RLS Pharma acquisition. An underappreciated development is the lapse of several conditional share and appreciation rights, which reduces potential future dilution and simplifies Telix’s capital structure, refining how...

If you are wondering whether BHP Group at around A$49.37 offers solid value or is pricing in too much optimism, it helps to step back and look at what the recent share performance and fundamentals are actually saying. Over the last week the stock return is 4.3%, over 30 days it is 11.6%, year to date it is 7.9%, and over the past year it is 28.8%, with a 3 year return of 15.7% and a 5 year return of 67.3%. These figures may influence how much upside or downside you feel is left. Recent news...

Neuren Pharmaceuticals (ASX:NEU) moved back into focus after partner Acadia Pharmaceuticals projected DAYBUE global net sales of about US$700 million by 2028, along with FDA approval of the new DAYBUE STIX powder formulation. See our latest analysis for Neuren Pharmaceuticals. Even after a recent 3.7% pullback in the 1 day share price return to A$19.71, Neuren’s 7 day share price return of 5.1% and 1 year total shareholder return of 60.5% suggest momentum has been supported by DAYBUE updates...

In recent days, coverage of Whitehaven Coal has focused on its cash flow generation, cost control and production efficiency within the Australian coal and energy sector, comparing these metrics with other ASX 100 companies. This renewed scrutiny of operating performance and cash flow efficiency offers readers a clearer lens on how Whitehaven Coal stacks up against large domestic peers. We’ll now explore how this spotlight on cash flow discipline and operational efficiency may influence...

South32 (ASX:S32) is scheduled to present at the Future Minerals Forum 2026 in Riyadh on 14 January, with CEO Graham Kerr set to speak. This presentation slot often draws investor attention to management commentary. See our latest analysis for South32. South32's recent momentum has been strong, with a 1 month share price return of 20.35% and a 90 day share price return of 28.57%. The 1 year total shareholder return of 22.30% sits against a more muted 3 year total shareholder return of a 1.77%...

Recent insider buying at Pro Medicus (ASX:PME), including on market purchases by senior executives and directors during the recent share price pullback, has drawn fresh attention to a stock that remains under technical selling pressure. See our latest analysis for Pro Medicus. At a share price of A$206.39, Pro Medicus is still in a clear technical downtrend, with a 30 day share price return of an 8.70% decline and a 90 day share price return of a 27.73% decline. Its 3 year total shareholder...

The Australian market today presents a mixed outlook, with the Aussie dollar inching closer to 67 cents against the USD and equities poised for a flat opening. For investors interested in exploring beyond well-known names, penny stocks—typically smaller or newer companies—offer intriguing possibilities. Despite the term's outdated feel, these stocks can still provide surprising value when backed by solid financials, offering potential for significant returns and stability.

In recent ASX trading, the S&P/ASX 200 reached a two-month high as strength in commodities-related sectors, particularly lithium, gold, and silver, lifted the index, while company updates such as Endeavour Group’s softer preliminary earnings and Lynas Rare Earths’ CEO transition also drew attention. What stands out is the broad commodity-led upswing, with lithium prices jumping very large over two sessions, signalling rising investor appetite for energy-transition exposures and helping pull...